Skip to main content

Advertisement

SpringerLink
Log in

The new diabetes inhalers: New tools for the clinician

  • Invited Commentary
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Estall JL, Drucker DJ: Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 2006, 12:1731–1750.

    Article  PubMed  CAS  Google Scholar 

  2. Levovitz HE: Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. Endocr Pract 2006, 12(suppl 1):142–147.

    Google Scholar 

  3. Holst JJ: Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006, 49:253–260.

    Article  PubMed  CAS  Google Scholar 

  4. White JR Jr, Campbell RK, Hirsch IB: Novel insulins and strict glycemic control. Analogues approximate normal insulin secretory response. Postgrad Med 2003, 113:30–36.

    PubMed  Google Scholar 

  5. Graff MR, McClanahan MA: Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther 1998, 20:486–496.

    Article  PubMed  CAS  Google Scholar 

  6. Zambanini A, Newson RB, Maisey M, et al.: Injection-related anxiety in insulin-treated diabetes. Diab Res Clin Pract 1999, 46:239–246.

    Article  CAS  Google Scholar 

  7. Hunt LM, Valenzuela MA, Pugh JA: NIDDM patients’ fears and hopes about insulin therapy. Diabetes Care 1997, 20:292–298.

    Article  PubMed  CAS  Google Scholar 

  8. Wallace TM, Matthews DR: Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. Q J Med 2000, 93:369–374.

    CAS  Google Scholar 

  9. Cefalu WT: Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. Ann Med 2001, 33:579–586.

    PubMed  CAS  Google Scholar 

  10. Gässlen M: Über inhalation von insulin. Klin Wochenschr 1925, 4:71.

    Article  Google Scholar 

  11. Heinemann L, Pfutzner A, Heise T: Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001, 7:1327–1351.

    Article  PubMed  CAS  Google Scholar 

  12. Heinemann L: Alternative delivery routes: inhaled insulin. Diabetes Nutr Metab 2002, 15:417–422.

    PubMed  CAS  Google Scholar 

  13. Heinemann L, Traut T, Heise T: Time-action profile of inhaled insulin. Diabet Med 1997, 14:63–72.

    Article  PubMed  CAS  Google Scholar 

  14. Rave K, Bott S, Heinemann L, et al.: Time-action profile of an inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005, 28:1077–1082.

    Article  PubMed  CAS  Google Scholar 

  15. Quattrin T, Belander A, Bohannon NJ, Schwartz SL: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004, 27:2622–2627.

    Article  PubMed  CAS  Google Scholar 

  16. Skyler JS, Weinstock RS, Raskin P, et al.: Use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects; a 6-month, randomized, comparative trial. Inhaled Insulin Phase III Type 1 Diabetes Study Group. Diabetes Care 2005, 28:1630–1635.

    Article  PubMed  CAS  Google Scholar 

  17. Garg S, Rosenstock J, Silverman BL, et al.: Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006, 49:891–899.

    Article  PubMed  CAS  Google Scholar 

  18. Hollander PA, Blonde L, Rowe R, et al.: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6 month, randomized, comparative trial. Diabetes Care 2004, 27:2356–2362.

    Article  PubMed  CAS  Google Scholar 

  19. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA: Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004, 27:1318–1323.

    Article  PubMed  Google Scholar 

  20. Rosenstock J, Zinman B, Murphy LJ, et al.: Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005, 143:549–558.

    PubMed  CAS  Google Scholar 

  21. Cefalu WT, Rosenstock J, Klioze S, et al.: Sustained efficacy and tolerability of inhaled insulin (Exubera). Therapy over 2 years: patients with type 2 diabetes [abstract]. Diabetologia 2006, 49(suppl 1):abstract 1004.

  22. Hollander PA, Krasner A, Klioze S, et al.: Body weight changes associated with insulin therapy: a retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in 5 controlled phase 3 trials [abstract]. Diabetologia 2006, 49(suppl 1):abstract 1003.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nutrition and Chronic Diseases, Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA, 70808, USA

    William T. Cefalu MD

Authors
  1. William T. Cefalu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William T. Cefalu MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cefalu, W.T. The new diabetes inhalers: New tools for the clinician. Curr Diab Rep 7, 165–167 (2007). https://doi.org/10.1007/s11892-007-0026-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-007-0026-2

Keywords

Search

Navigation